Twist Bioscience stock fell 6.78 percent while its CEO sold shares
Published on 10/08/2026 at 04:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Twist Bioscience (ISIN US90184D1000) was last at USD 155.65 on Nasdaq on October 7, 2026 at 4:00 p.m. EDT, down 6.78 percent. A MarketBeat report dated October 7, 2026 said Chief Executive Officer Emily Leproust sold 4,548 shares on October 5 at an average price of USD 202.15 under a pre-arranged Rule 10b5-1 plan.
CEO sale meets strong growth
The transaction reduced Leproust's reported ownership by 0.80 percent and left her with 562,760 shares, according to MarketBeat. The filing was executed under a trading plan, a detail that distinguishes the reported transaction from an open-ended discretionary sale.
Twist's fiscal third quarter ended June 30, 2026, produced revenue of USD 118.38 million, up 23.2 percent from USD 96.06 million in the year-ago quarter. Markets Insider reported that the company also posted a GAAP net loss of USD 35.05 million, compared with a net profit of USD 20.39 million in the prior-year quarter.
Revenue beats while EPS lags
The operating picture is therefore mixed in a precise way. Fiscal Q3 revenue exceeded the USD 114.55 million consensus estimate, but GAAP EPS was a loss of USD 0.56, missing the USD 0.51 loss estimate by USD 0.05, according to MarketBeat. The contrast leaves revenue momentum as the stronger current metric, while profitability remains the central counterweight.
Analyst target stays below price
MarketBeat lists a Moderate Buy consensus from 12 analysts and an average target price of USD 126.18. Separately, Markets Insider reported on October 7, 2026 that Barclays maintained a Buy rating and set a USD 215.00 target, up from USD 112.00.
That spread shows why the stock's growth profile and valuation are pulling in different directions. The average target is below the October 7 price, while Barclays' published target is above it, leaving analyst views unusually dispersed around the same company.
Nasdaq price and market value
Twist Bioscience was last at USD 155.65 on Nasdaq on October 7, 2026 at 4:00 p.m. EDT. The session range was USD 152.50 to USD 167.29, volume was 5,894,998 shares, and the 52-week range was USD 23.30 to USD 219.71; market capitalization stood at USD 9.7 billion.
Key facts on Twist Bioscience stock
- Company: Twist Bioscience Corporation
- ISIN: US90184D1000
- Ticker: TWST
- Trading venue: NASDAQ
- Price (as of October 7, 2026, 4:00 p.m. EDT): USD 155.65
- Market capitalization: USD 9.7 billion (as of October 7, 2026)
- 52-week range: USD 23.30-219.71 (as of October 7, 2026)
- Sector / Industry: Health Care / Biotechnology
More news and analyses on Twist Bioscience stock are available on the company topic page.
